{"url_path":"/sec/sgmt/8-k/2026-04-27/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-048971-index.html","accession_number":"0001104659-26-048971","cik":"0001400118","ticker":"SGMT","issuer_name":"Sagimet Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-048971-index.html","primary_entity_key":"0001400118","primary_entity_name":"Sagimet Biosciences Inc."},"word_count":449,"has_tables":true,"body_markdown":"**Item 2.02**\n**Results of Operations and Financial Condition.**\n\n \n\nSagimet Biosciences, Inc. (the “Company”)\nis furnishing with this Current Report on Form 8-K (the “Current Report”) certain unaudited preliminary financial information\nfor the Company’s fiscal quarter ended March 31, 2026.\n\n \n\n**Certain Unaudited Preliminary Financial\nInformation**\n\n \n\nThe Company estimates that its cash, cash equivalents and marketable\nsecurities were approximately $104.5 million as of March 31, 2026. This amount is unaudited and preliminary and is subject to completion\nof financial closing procedures, including the completion of management’s reviews. As a result, this amount reflects the Company’s\npreliminary estimate with respect to such information, based on information currently available for management, and may vary from the\nCompany’s actual financial position as of March 31, 2026. Further, this preliminary estimate is not a comprehensive statement\nor estimate of the Company’s financial data or financial condition as of March 31, 2026. The unaudited preliminary financial\ndata included in this Current Report on Form 8-K have been prepared by, and are the responsibility of, the Company’s management\nteam. KPMG LLP, the Company’s independent registered public accounting firm, has not audited, reviewed, examined, compiled, nor\napplied agreed-upon procedures with respect to the unaudited preliminary financial data. Accordingly, KPMG LLP does not express an opinion\nor any other form of assurance with respect thereto. It is possible that the Company may identify items that require the Company to make\nadjustments to the financial information set forth above. This preliminary estimate should not be viewed as a substitute for financial\nstatements prepared in accordance with generally accepted accounting principles in the United States and it is not necessarily indicative\nof the balance to be achieved in any future period. Additional information and disclosure would be required for a more complete understanding\nof the Company’s financial position and results of operations as of March 31, 2026. Accordingly, no undue reliance should be\nplaced on this preliminary estimate. The estimates should be read together with the Company’s audited consolidated financial statements\nand related notes and the Company’s other financial information reported in the Company’s Annual Report on Form 10-K\nfor the fiscal year ended December 31, 2025. The Company undertake no obligation to update or revise these amounts as a result of\nnew information or otherwise.\n\n \n\nThe information furnished pursuant to this Item 2.02 is intended to\nbe furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended\n(the “**Exchange Act**”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated\nby reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing."}